Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis

Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Weihong Zhao(Chinese PLA General Hospital), Jin Yang(Shanxi Medical University), Xinlan Liu(Yunnan Agricultural University), Caiwen Du(Shenzhen University), Huihui Li(Sichuan University), Qiang Liu(Sun Yat-sen University), Xiaojia Wang(Wenzhou Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Lili Sheng(First Affiliated Hospital of Wannan Medical College), Yuee Teng(First Hospital of China Medical University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Man Li(Dalian Medical University), Yanxia Shi(Sun Yat-sen University)
Cancer Research
February 15, 2022
10.1158/1538-7445.sabcs21-p1-16-02
Cited by 0

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743